The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer
1 Views
administrator
07/17/23
Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab(TSR-042) in patients with microsatellite instability–high (MSI-H) and microsatellite stable (MSS) endometrial cancer.
-
Category
Show more
Facebook Comments
No comments found